Study Finds Less Advanced Disease in Recent ATTR-CM Trials

Patients enrolled in more recent clinical trials for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) exhibited baseline characteristics consistent with less advanced disease than those in earlier trials, according to a study published in Progress in Cardiovascular Diseases.

Across recent clinical trials, 12-month all-cause mortality in the placebo groups has decreased significantly: from 9% (ATTR-ACT, 2013–2015) to 6.9% (ATTRibute-CM, 2019–2020), 5.6% (APOLLO-B, 2019–2021), and finally 4.3% to 5.5% in the HELIOS-B study (2019–2021).

By analyzing 13 trials conducted between 2008 and 2022, a team of researchers identified a clear shift toward diagnosing and enrolling patients with ATTR-CM at earlier stages of the disease.